New study tracks heart drug Vericiguat's safety in japanese patients

NCT ID NCT05666518

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study follows 1,400 Japanese adults with chronic heart failure to see how safe the drug vericiguat is in everyday use. Half will take vericiguat plus standard care, the other half standard care alone. Researchers will track side effects, blood pressure, and heart-related deaths over two years. The goal is to gather real-world safety information, not to prove the drug works better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vericiguat (Verquvo)
What this could lead to: If successful, this study could provide real-world safety data on vericiguat for Japanese patients with chronic heart failure, potentially supporting its broader use.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by factors other than the drug. It focuses on safety, not proving the drug works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEART FAILURE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Japanese registries
RECRUITING

Multiple Locations, Many Locations, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.